Nkgen Biotech Inc. (NKGN)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
NKGN Chart
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGen Biotech (NASDAQ: NKGN ) stock is rocketing higher on Thursday as the clinical-stage biotechnology company prepares to present new biomarker data on SNK01. This is the company's treatment candidate for Alzheimer's disease.
NKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring Today
NKGen Biotech (NASDAQ: NKGN ) stock is taking off on Monday after the clinical-stage biotechnology company got an update on its Phase 2 clinical trial. The company says that its Safety Review Committee has given it the go-ahead to start its Phase 2 clinical study of SNK01.
Nkgen Biotech Inc. Dividends
Nkgen Biotech Inc. Earnings
| 10 Sep 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 10 Sep 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 19 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Sep 2024 Date | | - Cons. EPS | - EPS |
| 10 Sep 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 10 Sep 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 19 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Sep 2024 Date | | - Cons. EPS | - EPS |
Nkgen Biotech Inc. (NKGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Nkgen Biotech Inc. ever had a stock split?
Nkgen Biotech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Paul Y. Song CEO | NASDAQ (NMS) Exchange | 65488A101 Cusip |
| US Country | 63 Employees | - Last Dividend | - Last Split | 13 Jul 2021 IPO Date |
Overview
NKGen Biotech, Inc. is a trailblazing clinical-stage biotechnology company rooted in the city of Santa Ana, California. Since its inception in 2017, NKGen has been at the forefront of developing innovative therapies derived from natural killer (NK) cells, a type of lymphocyte critical in the immune response to tumors and viral infections. The company's ambitious research and development activities focus on harnessing the power of autologous, allogeneic, and chimeric antigen receptor-modified natural killer (CAR-NK) cells, aiming to pioneer treatments that can significantly improve patient outcomes in the realm of cancer and beyond.
Products and Services
- SNK01
An autologous NK cell therapy currently in Phase 1 clinical trials. SNK01 is being developed as a cutting-edge treatment that utilizes a patient's own Natural Killer (NK) cells, which are then enhanced and reinfused into the patient. This therapy is designed to target and eliminate cancer cells, offering a personalized approach to cancer treatment.
- SNK02
An allogeneic NK cell therapy, also in Phase 1 clinical trials. Unlike SNK01, SNK02 is derived from healthy donors rather than the patient, which potentially allows for immediate use without the need for cell collection and customization. SNK02 aims to provide a universally accessible NK cell therapy, potentially revolutionizing the way certain cancers are treated.
Contact Information
